cizolirtine has been researched along with oxybutynin in 3 studies
| Studies (cizolirtine) | Trials (cizolirtine) | Recent Studies (post-2010) (cizolirtine) | Studies (oxybutynin) | Trials (oxybutynin) | Recent Studies (post-2010) (oxybutynin) |
|---|---|---|---|---|---|
| 22 | 5 | 2 | 2,607 | 619 | 1,670 |
| Protein | Taxonomy | cizolirtine (IC50) | oxybutynin (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 2.5951 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.027 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.002 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.0032 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0035 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.0027 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 2.5951 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.6 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.4288 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.792 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.0855 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.0242 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Soljanik, I | 1 |
| Abadías, M; Brod'ák, M; Pavlík, I; Schraml, P; Sust, M; Villoria, J; Vsetica, J; Zát'ura, F | 1 |
| Costantini, E; Lazzeri, M | 1 |
1 trial(s) available for cizolirtine and oxybutynin
| Article | Year |
|---|---|
Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Adult; Chi-Square Distribution; Confidence Intervals; Czech Republic; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Middle Aged; Muscarinic Antagonists; Pyrazoles; Quality of Life; Spain; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2010 |
2 other study(ies) available for cizolirtine and oxybutynin
| Article | Year |
|---|---|
Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2010 |
Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
Topics: Clinical Trials, Phase II as Topic; Humans; Mandelic Acids; Muscarinic Antagonists; Pyrazoles; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2010 |